

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

**Macquarie Group Limited**

ABN 94 122 169 279

1 Elizabeth Street  
Sydney NSW 2000  
GPO Box 4294  
Sydney NSW 1164  
AUSTRALIA

Telephone (61 2) 8232 3333  
Facsimile (61 2) 8232 3019  
Internet <http://www.macquarie.com>



# ASX/Media Release

## **Macquarie Group Limited – Macquarie Group Capital Notes 7 Replacement Prospectus**

**SYDNEY, Tuesday, 27 August 2024** – Macquarie Group Limited (ASX: MQG; ADR: MQBKY) (“MGL”) announces that a Replacement Prospectus for the Macquarie Group Capital Notes 7 (“MCN7”) was lodged with the Australian Securities and Investments Commission (“ASIC”) and the ASX today. The Replacement Prospectus is also available at [www.macquarie.com/MCN7](http://www.macquarie.com/MCN7)

### **Further information**

MCN7 are complex and not suitable for all investors. Potential investors should read the Replacement Prospectus in its entirety before deciding whether to apply to invest in MCN7. If any part of the Replacement Prospectus is unclear, we recommend seeking guidance from a financial advisor or other professional adviser.

If you have any questions about the MCN7, you should seek advice from your financial adviser or other professional adviser. If you have questions about the Offer, you can email the Registrar at [MCN7Offer@linkmarketservices.com.au](mailto:MCN7Offer@linkmarketservices.com.au) or call the MCN7 Offer Information Line on 1300 883 072 (within Australia) or on +61 1300 883 072 (outside Australia) (Monday to Friday 8:30am - 7:30pm, AEST) during the Offer Period. Applicants under the Broker Firm Offer should call their Syndicate Broker.

### **Definitions**

Unless otherwise defined, capitalised words used in this announcement have the meanings given to them in the Replacement Prospectus.

### **Disclaimer**

The information provided in this announcement and the Replacement Prospectus is not personal investment advice and has been prepared without taking into account your investment objectives, financial situation or particular needs

(including financial and taxation issues). It is important that you read the Replacement Prospectus in full before deciding to invest in MCN7 and consider the risks that could affect the performance of MCN7.

#### **NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES**

This announcement does not constitute an offer of any securities (including the MCN7) for sale or issue. No action has been taken to register or qualify MCN7 or the Offer or to otherwise permit a public offering of MCN7 outside Australia. In particular, this announcement does not constitute an offer of securities for sale in the United States. Neither the MCN7 nor the MGL Ordinary Shares have been or will be registered under the U.S. Securities Act of 1933 (the “**Securities Act**”) or the securities laws of any state or other jurisdiction of the United States, and they may not be offered or sold in the United States or to, or for the benefit of, any U.S. person (as defined in Regulation S under the Securities Act) except pursuant to a transaction exempt from, or not subject to, the registration requirements of the Securities Act and the securities laws of any state or other jurisdiction of the United States.

## Contacts

### **Sam Dobson**

Macquarie Group Investor Relations

+61 2 8232 9986

### **Lisa Jamieson**

Macquarie Group Media Relations

+61 2 8232 6016

Authorised for release to the ASX by the Head of Investor Relations, Sam Dobson